ABSOLUTE EASI TARGET IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF DATA FROM THE MEASURE UP 1 AND 2 STUDIES

被引：0
|
作者：
Prajapatil, Vimal [1 ,2 ,3 ,4 ,5 ,6 ]
Simpson, Eric L. [7 ]
Thyssen, Jacob P. [8 ]
Chovatiya, Raj [9 ]
Lane, Michael [10 ]
Teixeira, Henrique [10 ]
Calimlim, Brian [10 ]
Silverberg, Jonathan I. [11 ]
机构：
[1] Univ Calgary, Div Dermatol, Dept Med, Calgary, AB, Canada
[2] Univ Calgary, Sect Community Pediat, Dept Pediat, Calgary, AB, Canada
[3] Univ Calgary, Sect Pediat Rheumatol, Dept Pediat, Calgary, AB, Canada
[4] Skin Hlth & Wellness Ctr, Calgary, AB, Canada
[5] Dermatol Res Inst, Calgary, AB, Canada
[6] Prob Med Res, Calgary, AB, Canada
[7] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[8] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
[9] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA
[10] AbbVie Inc, N Chicago, IL USA
[11] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P4.17
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [21] RAPID QUALITY-OF-LIFE IMPROVEMENT WITH UPADACITINIB WITH OR WITHOUT TOPICAL CORTICOSTEROIDS (TCS) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM 3 PHASE 3 STUDIES (MEASURE UP 1, MEASURE UP 2, AND AD UP)
    Eyerich, Kilian
    Lynde, Charles W.
    Calimlim, Brian M.
    Liu, Meng
    Ladizinski, Barry
    Warren, Richard B.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 34 - 34
  • [22] Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
    Prajapati, Vimal H.
    Bunick, Christopher G.
    Eyerich, Kilian
    Gold, Linda Stein
    Galimberti, Fabrizio
    Calimlim, Brian
    Teixeira, Henrique
    Hu, Xiaofei
    Yang, Yang
    Sancho, Cristina
    Grada, Ayman
    Irvine, Alan D.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [23] Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials
    Gold, Linda Stein
    Thaci, Diamant
    Thyssen, Jacob P.
    Gooderham, Melinda
    Laquer, Vivian
    Natalie, Chitra R.
    Zhao, Fangyi
    Meskimen, Eric
    ElMaraghy, Hany
    Montmayeur, Sonia
    Jimenez, Gemma
    de Bruin-Weller, Marjolein
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [24] EASI-75 interpretation from a patient perspective - a phase 2b post-hoc analysis of dupilumab in adults with moderate-to-severe atopic dermatitis
    Poulin, Y.
    Tyring, S.
    Kimura, T.
    Andria, M.
    Ghorayeb, E.
    Eckert, L.
    Chao, J.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 70 - 70
  • [25] Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective
    Yeung, Jensen
    Gooderham, Melinda J.
    Hong, H. Chih-Ho
    Lynde, Charles
    Prajapati, Vimal H.
    Lansang, Perla
    Turchin, Irina
    Wiseman, Marni
    Jack, Carolyn
    Ramien, Michele
    Purdy, Kerri
    Grewal, Parbeer
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : 372 - 375
  • [26] Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis
    Paller, Amy S.
    Eichenfield, Lawrence F.
    Irvine, Alan D.
    Flohr, Carsten
    Wollenberg, Andreas
    Barbarot, Sebastien
    Bangert, Christine
    Spergel, Jonathan M.
    Selfridge, Andrew
    Biswas, Pinaki
    Fan, Haiyun
    Alderfer, Justine
    Watkins, Melissa
    Koppensteiner, Herwig
    ALLERGY, 2025,
  • [27] Treatment of moderate-to-severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry
    Traidl, Stephan
    Heinrich, Luise
    Siegels, Doreen
    Heratizadeh, Annice
    Kind, Barbara
    Haufe, Eva
    Abraham, Susanne
    Schaefer, Thomas
    Augustin, Matthias
    Harder, Inken
    Pinter, Andreas
    Schaekel, Knut
    Wollenberg, Andreas
    Ertner, Konstantin
    Ramaker-Brunke, Jutta
    Bong, Anne
    Quist, Sven
    Gorriahn-Maiterth, Hannah
    Schenck, Florian
    Sticherling, Michael
    Effendy, Isaak
    Schwarz, Beate
    Handrick, Christiane
    Asmussen, Andrea
    Weidinger, Stephan
    Schmitt, Jochen
    Werfel, Thomas
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (10) : e887 - e891
  • [28] BUDGET IMPACT ANALYSIS OF TRALOKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE UK
    Chalmers, K.
    Sawyer, L.
    Sohrt, A.
    Robinson, S.
    Ryttig, L.
    Rinciog, C.
    VALUE IN HEALTH, 2022, 25 (12) : S124 - S124
  • [29] Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Prajapati, Vimal H.
    Rosmarin, David
    Shumack, Stephen
    Calimlim, Brian M.
    Takemoto, Shunya
    Hu, Xiaofei
    Ladizinski, Barry
    Warren, Richard B.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E81 - E81
  • [30] Efficacy and Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Meta-Analysis
    Meher, Bikash R.
    Mishra, Archana
    Behera, Biswanath
    Ponnusamy, Subashri
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
12345